Transaction in own shares (1235701)
September 23 2021 - 11:30AM
UK Regulatory
Arix Bioscience PLC (ARIX) Transaction in own shares 23-Sep-2021
/ 17:30 GMT/BST Dissemination of a Regulatory Announcement,
transmitted by EQS Group. The issuer is solely responsible for the
content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Transaction in own shares
LONDON, 23 September 2021: Arix Bioscience plc ("Arix" or "the
Company") (LSE:ARIX), a global venture capital company focused on
investing in and building breakthrough biotech companies, today
announces that it purchased the following number of its ordinary
shares of 0.001 pence each on the London Stock Exchange from
Jefferies International Limited as part of a buyback programme
announced on 22 March 2021.
Date of purchase 23 September 2021
Aggregate number of shares purchased 34,000
Highest price paid per share 161.00p
Lowest price paid per share 161.00p
Average price paid per share 161.00p
Arix intends to retain the purchased shares in treasury.
Following settlement of the above purchase, Arix will have
129,860,800 ordinary shares of 0.001 pence each in issue (excluding
5,748,853 ordinary shares of 0.001p each held in treasury). This
number represents the total voting rights in Arix and may be used
by shareholders as the denominator for the calculations by which
they can determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure and Transparency
Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No.
596/2014 (as incorporated into UK domestic law by the European
Union (Withdrawal) Act 2018), the schedule below contains detailed
information of the individual trades made by Jefferies
International Limited as part of the buyback programme.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Manel Mateus
+44 (0)20 8078 4357
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number
23/09/2021 11:13:41 34,000 161.00 London Stock Exchange 00263648784TRLO1
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: POS
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares
Sequence No.: 122901
EQS News ID: 1235701
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1235701&application_name=news
(END) Dow Jones Newswires
September 23, 2021 12:30 ET (16:30 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024